Achieved a sustained viral response in 83% of patients with hepatitis C protease inhibitor for HCV New Boehringer Ingelheim
‘The final results of the Silen-C1 and two studies have demonstrated the potential for an excellent performance of this protease inhibitor once daily in a wide range of HCV patients,’ said Prof. ‘The current standard of care for HCV is not effective for many patients. The cure rate achieved viral protease inhibitors, such as IB [...]
